Debiopharm Research and Manufacturing S.A., rue du Levant 146, 1920 Martigny, Switzerland; PEPITE EA4267, Univ. Bourgogne Franche-Comté, F- 25000 Besançon, France.
Debiopharm Research and Manufacturing S.A., rue du Levant 146, 1920 Martigny, Switzerland.
Int J Pharm. 2018 Jan 30;536(1):222-230. doi: 10.1016/j.ijpharm.2017.11.050. Epub 2017 Nov 23.
Active Freeze Drying allows for producing lyophilised powders by progressive agitation of frozen blocks undergoing sublimation. One potential application of this process is the formulation design of unstable nanosuspensions for oral drug delivery, as here shown for nanocrystal-based ketoconazole powder. With this technique, a critical vapour flow needs to be achieved in order to obtain reasonable process yields (>78%). The size distribution of powder particles (median size between 21 and 44 μm) was affected by the nanocrystal concentration and the drug-to-stabilizer ratio. This was assumed to be related to the mechanical strength of the solid network from which the powder particles break off. The adjustments of the drug-to-stabilizer ratio and the freezing procedure proved to play a major role in improving powder redispersibility. However, differences in powder redispersibility did not translate into significant changes in in-vitro dissolution rates. Active Freeze Drying has confirmed to be a promising tool to efficiently produce redispersible nanocrystal powders.
真空冷冻干燥允许通过对经历升华的冷冻块进行渐进搅拌来生产冻干粉末。该过程的一个潜在应用是为口服药物输送设计不稳定的纳米混悬剂的配方设计,这里以基于纳米晶体的酮康唑粉末为例。使用这种技术,需要达到临界蒸汽流量才能获得合理的工艺收率(>78%)。粉末颗粒的尺寸分布(中值尺寸在 21 到 44μm 之间)受纳米晶体浓度和药物与稳定剂之比的影响。这被认为与粉末颗粒脱落的固体网络的机械强度有关。调整药物与稳定剂的比例和冷冻程序被证明在改善粉末再分散性方面起着重要作用。然而,粉末再分散性的差异并没有转化为体外溶解速率的显著变化。真空冷冻干燥已被证实是一种很有前途的工具,可以有效地生产可再分散的纳米晶体粉末。